Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Johnston, Elleson Schurtz, Elizabeth Tourville, Tamekia Jones, Allison Boemer, D. Giel (2016)
Risk Factors Associated with Severity and Outcomes in Pediatric Patients with Hemorrhagic Cystitis.The Journal of urology, 195 4 Pt 2
Juan Li, G. Dai, Zhuoli Zhang (2015)
General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade — a single-center retrospective studyClinical Rheumatology, 34
G. Guenno, A. Mahr, C. Pagnoux, R. Dhôte, L. Guillevin (2011)
Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides.Arthritis and rheumatism, 63 5
C. Ekhart, S. Rodenhuis, P. Smits, J. Beijnen, A. Huitema (2008)
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatinPharmacogenetics and Genomics, 18
FB Karassa (2006)
Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritisN Engl J Med., 354
L. Grochow, M. Colvin (1979)
Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 4
P. Monach, Lindsay Arnold, P. Merkel (2010)
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.Arthritis and rheumatism, 62 1
T. Brummaier, E. Pohanka, A. Studnicka-Benke, H. Pieringer (2013)
Using cyclophosphamide in inflammatory rheumatic diseases.European journal of internal medicine, 24 7
HS Koo, Yc Kim, S. Lee, D. Kim, K. Oh, K. Joo, Y.S. Kim, C. Ahn, Js Han, S. Kim, H. Chin (2011)
The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritisLupus, 20
C. Ekhart, V. Doodeman, S. Rodenhuis, P. Smits, J. Beijnen, A. Huitema (2008)
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamidePharmacogenetics and Genomics, 18
R. Kloos, J. Boelens, T. Jong, B. Versluys, M. Bierings (2013)
Hemorrhagic cystitis in a cohort of pediatric transplantations: incidence, treatment, outcome, and risk factors.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 19 8
G. Hale, G. Hale, R. Rochester, H. Heslop, H. Heslop, R. Krance, R. Krance, J. Gingrich, J. Gingrich, E. Benaim, E. Benaim, E. Horwitz, E. Horwitz, J. Cunningham, J. Cunningham, X. Tong, D. Srivastava, W. Leung, W. Leung, P. Woodard, P. Woodard, L. Bowman, L. Bowman, R. Handgretinger, R. Handgretinger (2003)
Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 9 11
T. Chan, Fu‐Keung Li, W. Hao, K. Chan, S. Lui, S. Tang, K. Lai (1999)
Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppressionLupus, 8
K. Takada, M. Arefayene, Z. Desta, Cheryl Yarboro, D. Boumpas, J. Balow, D. Flockhart, G. Illei (2004)
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.Arthritis and rheumatism, 50 7
Shi-long Zhong, Min Huang, Xiu-yan Yang, L. Liang, Yi-xi Wang, M. Romkes, W. Duan, E. Chan, Shufeng Zhou (2006)
Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.British journal of clinical pharmacology, 62 4
M. Gourley, Howard III, D. Scott, Cheryl Yarboro, E. Vaughan, J. Muir, D. Boumpas, J. Klippel, J. Balow, A. Steinberg (1996)
Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus NephritisAnnals of Internal Medicine, 125
Jonge de, AD Huitema, S Rodenhuis (2005)
Clinical pharmacokinetics of cyclophosphamideClin Pharmacokinet., 44
Joshua Kaplan, J. Wolf (2009)
Efficacy and survival associated with cystoscopy and clot evacuation for radiation or cyclophosphamide induced hemorrhagic cystitis.The Journal of urology, 181 2
E. Gorczyńska, D. Turkiewicz, K. Rybka, J. Toporski, K. Kałwak, A. Dyla, Zofia Szczyra, A. Chybicka (2005)
Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 11 10
C. Talar-Williams, Yasmine Hijazi, McClellan Walther, W. Linehan, Claire Hallahan, I. Lubensky, G. Kerr, Guy Hoffman, A. Fauci, M. Sneller (1996)
Cyclophosphamide-Induced Cystitis and Bladder Cancer in Patients with Wegener GranulomatosisAnnals of Internal Medicine, 124
N. Yılmaz, H. Emmungil, S. Gucenmez, G. Ozen, F. Yıldız, A. Balkarlı, G. Kimyon, B. Coşkun, I. Dogan, O. Pamuk, Ş. Yaşar, G. Cetin, A. Yazıcı, S. Esmen, Y. Çağatay, S. Yılmaz, A. Çefle, M. Sayarlıoğlu, T. Kaşifoğlu, O. Karadag, Y. Pehlivan, E. Dalkılıç, B. Kısacık, V. Çobankara, E. Erken, H. Direskeneli, K. Aksu, Ş. Yavuz (2015)
Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic DiseasesThe Journal of Rheumatology, 42
E. Reinhold-Keller, Nadja Beuge, U. Latza, K. Groot, H. Rudert, B. Nölle, Martin Heller, W. Gross (2000)
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.Arthritis and rheumatism, 43 5
Chen Ling-ya (2014)
Relationship between aldehyde dehydrogenase polymorphisms and cyclophosphamide-induced adverse effects in patients with systemic lupus erythematosusThe Chinese Journal of Clinical Pharmacology
D. Tashkin, R. Elashoff, P. Clements, J. Goldin, Michael Roth, Daniel Furst, E. Arriola, R. Silver, C. Strange, M. Bolster, J. Seibold, David Riley, V. Hsu, J. Varga, Dean Schraufnagel, A. Theodore, R. Simms, R. Wise, F. Wigley, B. White, V. Steen, C. Read, M. Mayes, E. Parsley, K. Mubarak, M. Connolly, J. Golden, M. Olman, B. Fessler, N. Rothfield, M. Metersky (2006)
Cyclophosphamide versus placebo in scleroderma lung disease.The New England journal of medicine, 354 25
M. Droller, Rein Saral, George Santos (1982)
Prevention of cyclophosphamide-induced hemorrhagic cystitis.Urology, 20 3
(1982)
Prevention of cyclophosphamideinduced hemorrhagic cystitis. Urology
J. Killen (2006)
Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.The New England journal of medicine, 354 7
C. Mukhtyar, L. Guillevin, M. Cid, B. Dasgupta, K. Groot, W. Gross, T. Hauser, B. Hellmich, D. Jayne, C. Kallenberg, P. Merkel, H. Raspe, C. Salvarani, David Scott, C. Stegeman, R. Watts, K. Westman, J. Witter, H. Yazici, R. Luqmani (2008)
EULAR recommendations for the management of primary small and medium vessel vasculitisAnnals of the Rheumatic Diseases, 68
Drugs - Real World Outcomes (2017) 4:175–182 DOI 10.1007/s40801-017-0112-y ORIGINAL RESEARCH ARTICLE Rare Cyclophosphamide-Induced Hemorrhagic Cystitis in a Chinese Population with Rheumatic Diseases 1 1 2 3 • • • • Liuqin Liang Donging Chen Xiaodong Wang Zheng Yang 1 1 1 • • Jun Zhou Zhongping Zhan Fan Lian Published online: 23 June 2017 The Author(s) 2017. This article is an open access publication Abstract hydration, and bladder irrigation. The other two were Objective The aim of this study was to investigate the unresponsive to the above treatment and finally had reso- prevalence, severity, risk factors, and treatment outcomes lution after cystectomy. The average resolution time of of cyclophosphamide (CYC)-induced hemorrhagic cystitis hematuria was 39.5 days (7–56 days). There were no (HC) in patients with rheumatic diseases. deaths in our cohort. Methods We collected the clinical data from 1284 con- Conclusion CYC-induced HC was rare and highly variable secutive patients admitted to The First Affiliated Hospital in Chinese patients with rheumatic diseases. Individualized of Sun Yat-Sen University who were treated with CYC treatment should be performed according to the severity of between 2006 and 2016, and then conducted a retrospective HC for each patient. More aggressive treatment strategies
Drugs - Real World Outcomes – Springer Journals
Published: Jun 23, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.